Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
completedphase_2

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

NCT03512288
completedphase_2

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

NCT03313050
completedphase_2

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
completedphase_1

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

NCT02955160

Clinical Trials (5)

Showing 5 of 5 trials
NCT03550313Phase 2

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Terminated
NCT03512288Phase 2

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

Completed
NCT03313050Phase 2

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Completed
NCT03313037Phase 2

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Completed
NCT02955160Phase 1

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5